VILDAGLIPTIN
Application
Vildagliptin has been used:as a dipeptidyl peptidase-4 (DPP4) inhibitor to study its effects on endoplasmic reticulum (ER) pathway under diabetic conditionsin pharmacological inhibition to investigate the kinetics of transposable element (TE) desilencing and confirm its dependence on DPF-3 (a P-granule-localized N-terminal dipeptidase) enzymatic activityto study its electrochemical properties and determinationin biological fluid and drug forms
Biochem/physiol Actions
Vildagliptin ia a selective inhibitor of dipeptidyl peptidase 4 (DPP4). This enzyme breaks down the incretins GLP-1 and GIP, gastrointestinal hormones that are released in response to a meal. By preventing GLP-1 and GIP inactivation, GLP-1 and GIP are able to potentiate the secretion of insulin and suppress the release of glucagon by the pancreas.
Vildagliptin may participate in lipid metabolism. It plays a key role in attenuating postprandial hypertriglyceridemia, reducing serum triglycerides, apolipoprotein B, and blood total cholesterol levels. Vildagliptin is used in diabetes mellitus type 2 (DM2) therapy and may also possess vasculoprotective properties. Vildagliptin also helps to improve mitochondrial dysfunction caused by diabetes.
| Colour | white to beige |
|---|---|
| InChI key | SYOKIDBDQMKNDQ-NHMCJKAESA-N |
| InChI | 1S/C17H25N3O2/c18-9-14-2-1-3-20(14)15(21)10-19-16-5-12-4-13(6-16)8-17(22,7-12)11-16/h12-14,19,22H,1-8,10-11H2/t12-,13+,14-,16+,17-/m0/s1 |
| Manufacturer | SIGMA-ALDRICH |
| Solubility | DMSO: 2 mg/mL, clear |
| Form | powder |
| Assay | ≥98% (HPLC) |
There are no downloads for this product.
